Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Abstract Purpose of Review Despite an overall reduction in lung cancer incidence and
mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Background The ALEX study demonstrated significantly improved progression-free survival
(PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung …

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …

Introduction Access to targeted therapies for lung cancer depends on the accurate
identification of patients' biomarkers through molecular testing. The International Association …

Purpose Tissue acquisition in lung cancer is vital for multiple reasons. Primary reasons
reported for molecular testing failure in lung cancer biopsy specimens include insufficient …

Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received
first-line treatment indication of advanced ALK+ NSCLC in various countries. In Ba/F3 cells …

Introduction The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non–
small-cell lung cancer (NSCLC) primarily involves ALK-directed tyrosine kinase inhibitors …